Trial Details

TERMINATED
Basic Information
Clinical ID c1254
Identifier NCT04277546
Trial Title Open-label Extension Study of Brazikumab in Ulcerative Colitis
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: Brazikumab Maintenance Dose|DRUG: Brazikumab Induction Dose
Participant Information
Sponsor AstraZeneca
City Chula Vista
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2020-03-03
Primary Completion Date 2023-10-10
Completion Date 2023-10-10